Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UCDCC#269: A Pilot Study of Interlesional IL-2 and Hypofractionated Radiotherapy in Patients With Metastatic Non-small Cell Lung Cancer Who Are Refractory to PD 1 / PD L1 Blockade.

NCT03224871 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT03224871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03224871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UCDCC#269: A Pilot Study of Interlesional IL-2 and Hypofractionated Radiotherapy in Patients With Metastatic Non-small Cell Lung Cancer Who Are Refractory to PD 1 / PD L1 Blockade.
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Completed
Start date
August 11, 2017
Completion date
January 10, 2020
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-small cell lung cancer